Patents Assigned to Novartis AG
  • Car-expressing cells against multiple tumor antigens and uses thereof
    Patent number: 11161907
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Daniel J. Powell, Jr.
  • Pyridinone derivatives and their use as selective ALK-2 inhibitors
    Patent number: 11160797
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sylvie Chamoin, Pier Luca D'Alessandro, Mika Lindvall, Dimitrios Lizos, Nikolaus Johannes Stiefl, Sylvie Teixeira-Fouchard, Thomas Ullrich, Sven Weiler
  • Polyomavirus neutralizing antibodies
    Patent number: 11161894
    Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Novartis AG
    Inventors: Johanna Abend, Zorica Dragic, Adam Lloyd Feire, Mark Knapp, Steven Kovacs, Elisabetta Traggiai, Lichun Wang, Yongqiang Wang, Danqing Wu, Qilong Wu, Fangmin Xu
  • Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
    Patent number: 11162065
    Abstract: The present disclosure relates to systems and methods for flow-through separation of paramagnetic particle-bound cells in a cell suspension containing both bound and unbound cells as well as systems and methods for removing paramagnetic particles from paramagnetic particle-bound cells or from a cell suspension with unbound cells. It further relates to a flow-through magnetic separation/debeading module and a flow-through spinning membrane debeading module.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Fabio Fachin, Rodney Rietze, Michael R. Greene, Lan Cao
  • Pharmaceutical dosage forms
    Patent number: 11160804
    Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 2, 2021
    Assignee: Novartis AG
    Inventor: Suzie Jesus Ribeiro
  • Regimens and methods of treating multiple sclerosis using ofatumumab
    Patent number: 11161909
    Abstract: The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 2, 2021
    Assignee: NOVARTIS AG
    Inventors: Erik Wallström, Marina Savelieva Praz, Algirdas Jonas Kakarieka Weisskopf, Joseph Michael Kahn
  • Method of detecting TIM-3 using antibody molecules to TIM-3
    Patent number: 11155620
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., The Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Cell bag rotator
    Patent number: 11154827
    Abstract: A cell bag rotator is constructed to slowly agitate a plurality of cell bags by rotation along a rotation axis that is at least partially horizontal. The cell bag rotator comprises a plurality of plates to which a respective cell bag is attached. The cell bag rotator is suitable for mixing cells with particles for performing various types of subsequent cell therapy processes on the cells.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 26, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Thomas Callahan, Charles Duffy, Jr.
  • CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
    Patent number: 11149076
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 19, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Syringe
    Patent number: 11147925
    Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 19, 2021
    Assignee: NOVARTIS AG
    Inventors: Andrew Bryant, Heinrich Buettgen, Wolfgang Papst, Marie Picci
  • Circulation of components during microfluidization and/or homogenization of emulsions
    Patent number: 11141376
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: October 12, 2021
    Assignee: NOVARTIS AG
    Inventors: Harald Rueckl, Hanno Scheffczik, Barbara Santry
  • Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same
    Patent number: 11135239
    Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: October 5, 2021
    Assignee: NOVARTIS AG
    Inventors: Christoph Bucher, Dietmar Flubacher, Jeremiah Douglas Foutch, Malay Ghosh, Johannes Franz Kluge, Zaixing Li, Cale Ry McAlister, Liladhar Murlidhar Waykole, Jens Sören Worthmann, Tingying Zhu
  • Inhibitors for treating diseases characterized by atrial enlargement or remodeling
    Patent number: 11135192
    Abstract: The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Christoph Schumacher, Thomas Holbro
  • Methods of treating immune related disorders using antibody-cytokine engrafted compositions
    Patent number: 11136366
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Nucleic acids encoding FGF21-Fc fusion proteins
    Patent number: 11129874
    Abstract: The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 28, 2021
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Container arrangement including a wireless communication device and method for operating the same
    Patent number: 11126909
    Abstract: A container arrangement (100) is disclosed, which is preferably destined for pharmaceutical products. The container arrangement includes a container body (110) and a first wireless communication systems (210) composed of a NFC system (210) including an NFC antenna (141). The container arrangement further includes a first and/or a second sensing-switching arrangement (143; 280) configured to include a preset status inhibiting a standardized operability of the first wireless communication system (210). The first sensing-switching arrangement (143) is configured to deregulate its preset status upon an initial opening event and the second sensing-switching arrangement (280) is configured to deregulate its preset status upon an unloading event.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: September 21, 2021
    Assignee: NOVARTIS AG
    Inventor: Andrew Bryant
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 11123348
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: September 21, 2021
    Assignee: Novartis AG
    Inventors: Agnes Biggart, Fang Liang, Casey Jacob Nelson Mathison, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Vince Yeh
  • Antibody-cytokine engrafted proteins and methods of use for immune related disorders
    Patent number: 11122825
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: September 21, 2021
    Assignee: Novartis AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies
    Patent number: 11124578
    Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 21, 2021
    Assignee: NOVARTIS AG
    Inventors: Christoph Heusser, James Rush, Karen Vincent
  • Complexes of IL-15 and IL-15Ralpha and uses thereof
    Patent number: 11110150
    Abstract: The present invention relates to agents that modulate interleukin-15 (“IL-15”) signal transduction or function (“Therapeutic Agents”) and the use ol” those agents to modulate immune function. The Therapeutic Agents target the interaction between IL-15 and its receptor and modulate IL-15-induced signal transduction. The Therapeutic Agents may be formulated with polymers, such as poly-?-1-?4-N-acetylglucosamine. for administration to a human subject to modulate IL-15-mediated immune function.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: September 7, 2021
    Assignees: NOVARTIS AG, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barbara K. Felber, Sergio Finkielsztein, George N. Pavlakis, John V. Vournakis